Contains Nonbinding Recommendations

Draft Guidance on Estradiol

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Estradiol

Dosage Form; Route: Gel; transdermal

Recommended Studies: One study

Type of study:	Bioequivalence study with pharmacokinetic endpoints
Design:	Single-dose, two-treatment, two-period, crossover design, in vivo
Strength:	0.1%
Subjects:	Postmenopausal women with no contraindication to estrogen therapy

Additional comments: 1 g of estradiol gel may be dosed as recommended in the reference listed drug (RLD) label to evenly cover the same amount of skin surface area for the test and reference products. An average baseline correction may be obtained by averaging 3 pre-application sampling times (-1.0, -0.5 and 0 hours).

Analytes to measure (in appropriate biological fluid): Estradiol in plasma

Bioequivalence based on (90% CI): Estradiol, using both baseline corrected and uncorrected data

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: Not applicable